Formulation of amphotericin B as nanosuspension for oral administration.
Kayser, O;
Olbrich, C;
Yardley, V;
Kiderlen, AF;
Croft, SL;
(2003)
Formulation of amphotericin B as nanosuspension for oral administration.
International journal of pharmaceutics, 254 (1).
pp. 73-75.
ISSN 0378-5173
DOI: https://doi.org/10.1016/s0378-5173(02)00686-5
Permanent Identifier
Use this Digital Object Identifier when citing or linking to this resource.
Amphotherin B was formulated in a nanosuspension as a new oral drug delivery system for the treatment of experimental visceral leishmaniasis. Amphotericin B (AmB) nanosuspensions were produced by high pressure homogenisation obtaining particles with a PCS diameter of 528 nm. Environmental stability was determined in artificial gastrointestinal fluids at different pH and electrolyte concentrations. In vivo efficacy was determined in a mouse model of visceral leishmaniasis. Following oral administration (5 mg kg(-1)), micronised amphotericin B did not show any curative effect. However, administrations of amphotericin B nanosuspension, reduced liver parasite load by 28.6% compared to untreated controls.
